Selleck Chemicals supplies over 3,000 inhibitors used in the study of cell signaling pathways. We actively tracks the latest science so our customers can rely on us to be the leading supplier of the newest inhibitors.
Company WebsiteIACS-010759 (IACS-10759) is a potent and selective oxidative phosphorylation inhibitor (IC50 < 10 nM) that blocks cellular respiration through inhibition of complex I.
More Information Supplier PageIACS-010759 (IACS-10759) is a potent and selective oxidative phosphorylation inhibitor (IC50 < 10 nM) that blocks cellular respiration through inhibition of complex I.
More Information Supplier PageIACS-010759 (IACS-10759) is a potent and selective oxidative phosphorylation inhibitor (IC50 < 10 nM) that blocks cellular respiration through inhibition of complex I.
More Information Supplier PageIACS-6274 (IPN60090), is a potent, selective and orally active glutaminase inhibitor with potential antineoplastic and immunostimulating activities.
More Information Supplier PageIACS-6274 (IPN60090), is a potent, selective and orally active glutaminase inhibitor with potential antineoplastic and immunostimulating activities.
More Information Supplier PageORY-1001 (RG-6016) 2HCl is an orally active and selective lysine-specific demethylase LSD1/KDM1A inhibitor with IC50 of
More Information Supplier PageORY-1001 (RG-6016) 2HCl is an orally active and selective lysine-specific demethylase LSD1/KDM1A inhibitor with IC50 of
More Information Supplier PageORY-1001 (RG-6016) 2HCl is an orally active and selective lysine-specific demethylase LSD1/KDM1A inhibitor with IC50 of
More Information Supplier PageORY-1001 (RG-6016) 2HCl is an orally active and selective lysine-specific demethylase LSD1/KDM1A inhibitor with IC50 of
More Information Supplier PageIAG933 (YAP-TEAD-IN-3) is a small molecule and acts as a YAP/TAZ-TEAD inhibitor. It also inhibits NCI-H2052 and can be used in research of tumor invasion and metastatic spread of solid tumors.
More Information Supplier PageIanalumab (Anti-TNFRSF13C / BAFFR / CD268) is a fully human combinatorial antibody library (HuCAL)-derived monoclonal antibody targeting the B-cell-activating factor receptor (BAFF-R), with potential anti-inflammatory and antineoplastic activities. MW : 145.5 KD.
More Information Supplier PageIanalumab (Anti-TNFRSF13C / BAFFR / CD268) is a fully human combinatorial antibody library (HuCAL)-derived monoclonal antibody targeting the B-cell-activating factor receptor (BAFF-R), with potential anti-inflammatory and antineoplastic activities. MW : 145.5 KD.
More Information Supplier PageIanalumab (Anti-TNFRSF13C / BAFFR / CD268) is a fully human combinatorial antibody library (HuCAL)-derived monoclonal antibody targeting the B-cell-activating factor receptor (BAFF-R), with potential anti-inflammatory and antineoplastic activities. MW : 145.5 KD.
More Information Supplier PageIAXO-102 is an antagonist of TLR4 targeting both MD-2 and CD14 co-receptors. IAXO-102 inhibits MAPK and p65 NF-κB phosphorylation and downregulates the expression of TLR4 dependent proinflammatory proteins. IAXO-102 inhibits experimental abdominal aortic aneurysm (AAA) development.
More Information Supplier PageIAXO-102 is an antagonist of TLR4 targeting both MD-2 and CD14 co-receptors. IAXO-102 inhibits MAPK and p65 NF-κB phosphorylation and downregulates the expression of TLR4 dependent proinflammatory proteins. IAXO-102 inhibits experimental abdominal aortic aneurysm (AAA) development.
More Information Supplier PageIbalizumab (Anti-CD4) is a humanised IgG4 monoclonal antibody, targeting C4. It prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research. MW:145.5 KD.
More Information Supplier PageIbalizumab (Anti-CD4) is a humanised IgG4 monoclonal antibody, targeting C4. It prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research. MW:145.5 KD.
More Information Supplier PageIbalizumab (Anti-CD4) is a humanised IgG4 monoclonal antibody, targeting C4. It prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research. MW:145.5 KD.
More Information Supplier PageIbandronate (BM-21.0955, BM-210955, RPR-102289A) is a highly potent nitrogen-containing bisphosphonate used for the treatment of osteoporosis.
More Information Supplier PageIbandronate (BM-21.0955, BM-210955, RPR-102289A) is a highly potent nitrogen-containing bisphosphonate used for the treatment of osteoporosis.
More Information Supplier PageIberdomide (CC-220) is a novel oral immunomodulatory compound that targets cereblon, part of the CRL4CRBN E3 ubiquitin ligase complex, with an IC50 of 60 nM in a competitive TR-FRET assay. Iberdomide (CC-220) induces apoptosis with antitumor and immunostimulatory activities.
More Information Supplier PageIberdomide (CC-220) is a novel oral immunomodulatory compound that targets cereblon, part of the CRL4CRBN E3 ubiquitin ligase complex, with an IC50 of 60 nM in a competitive TR-FRET assay. Iberdomide (CC-220) induces apoptosis with antitumor and immunostimulatory activities.
More Information Supplier PageIberdomide (CC-220) is a novel oral immunomodulatory compound that targets cereblon, part of the CRL4CRBN E3 ubiquitin ligase complex, with an IC50 of 60 nM in a competitive TR-FRET assay. Iberdomide (CC-220) induces apoptosis with antitumor and immunostimulatory activities.
More Information Supplier PageIberdomide (CC-220) is a novel oral immunomodulatory compound that targets cereblon, part of the CRL4CRBN E3 ubiquitin ligase complex, with an IC50 of 60 nM in a competitive TR-FRET assay. Iberdomide (CC-220) induces apoptosis with antitumor and immunostimulatory activities.
More Information Supplier PageIberdomide (CC-220) is a novel oral immunomodulatory compound that targets cereblon, part of the CRL4CRBN E3 ubiquitin ligase complex, with an IC50 of 60 nM in a competitive TR-FRET assay. Iberdomide (CC-220) induces apoptosis with antitumor and immunostimulatory activities.
More Information Supplier PageIberdomide (CC-220) is a novel oral immunomodulatory compound that targets cereblon, part of the CRL4CRBN E3 ubiquitin ligase complex, with an IC50 of 60 nM in a competitive TR-FRET assay. Iberdomide (CC-220) induces apoptosis with antitumor and immunostimulatory activities.
More Information Supplier PageIbiglustat succinate (Venglustat succinate) is a glucosylceramide (GlcCer) synthase inhibitor that blocks the formation of glucosylceramide.
More Information Supplier PageIBMX (Isobutylmethylxanthine, 1-Methyl-3-Isobutylxanthine) is a nonspecific inhibitor of phosphodiesterase (PDE) with IC50 values of 6.5±1.2, 26.3±3.9 and 31.7±5.3 μM for PDE3, 4 and 5 respectively. It may enhance the intracellular cAMP levels and also acts as an adenosine (A1) receptor antagonist.
More Information Supplier PageIBMX (Isobutylmethylxanthine, 1-Methyl-3-Isobutylxanthine) is a nonspecific inhibitor of phosphodiesterase (PDE) with IC50 values of 6.5±1.2, 26.3±3.9 and 31.7±5.3 μM for PDE3, 4 and 5 respectively. It may enhance the intracellular cAMP levels and also acts as an adenosine (A1) receptor antagonist.
More Information Supplier PageIBMX (Isobutylmethylxanthine, 1-Methyl-3-Isobutylxanthine) is a nonspecific inhibitor of phosphodiesterase (PDE) with IC50 values of 6.5±1.2, 26.3±3.9 and 31.7±5.3 μM for PDE3, 4 and 5 respectively. It may enhance the intracellular cAMP levels and also acts as an adenosine (A1) receptor antagonist.
More Information Supplier PageIBMX (Isobutylmethylxanthine, 1-Methyl-3-Isobutylxanthine) is a nonspecific inhibitor of phosphodiesterase (PDE) with IC50 values of 6.5±1.2, 26.3±3.9 and 31.7±5.3 μM for PDE3, 4 and 5 respectively. It may enhance the intracellular cAMP levels and also acts as an adenosine (A1) receptor antagonist.
More Information Supplier PageIBMX (Isobutylmethylxanthine, 1-Methyl-3-Isobutylxanthine) is a nonspecific inhibitor of phosphodiesterase (PDE) with IC50 values of 6.5±1.2, 26.3±3.9 and 31.7±5.3 μM for PDE3, 4 and 5 respectively. It may enhance the intracellular cAMP levels and also acts as an adenosine (A1) receptor antagonist.
More Information Supplier PageIbotenic acid((RS)-Ibotenic acid; DL-Ibotenic acid) is a neuroexcitatory amino acid originally isolated from Amanita species. It exhibits agonist activity at both N-methyl-D-aspartate (NMDA) and trans-ACPD) or metabolotropic quisqualate (Qm) receptor sites.
More Information Supplier PageIbotenic acid((RS)-Ibotenic acid; DL-Ibotenic acid) is a neuroexcitatory amino acid originally isolated from Amanita species. It exhibits agonist activity at both N-methyl-D-aspartate (NMDA) and trans-ACPD) or metabolotropic quisqualate (Qm) receptor sites.
More Information Supplier PageIbritumomab (anti-CD20) is a monoclonal antibody targeting anti-CD20 used to treat B-cell non-Hodgkin’s lymphoma. MW: 144.52 KD.
More Information Supplier PageIbritumomab (anti-CD20) is a monoclonal antibody targeting anti-CD20 used to treat B-cell non-Hodgkin’s lymphoma. MW: 144.52 KD.
More Information Supplier PageIbritumomab (anti-CD20) is a monoclonal antibody targeting anti-CD20 used to treat B-cell non-Hodgkin’s lymphoma. MW: 144.52 KD.
More Information Supplier PageIbrolipim (NO-1886) is an effective lipoprotein lipase (LPL) activator that increases LPL mRNA and LPL activity in adipose tissue, myocardium, and skeletal muscle.
More Information Supplier PageIbrutinib is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. Ibrutinib is applicable as a Btk ligand in the synthesis of a series of PROTACs including P13I.
More Information Supplier PageIbrutinib is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. Ibrutinib is applicable as a Btk ligand in the synthesis of a series of PROTACs including P13I.
More Information Supplier PageIbrutinib is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. Ibrutinib is applicable as a Btk ligand in the synthesis of a series of PROTACs including P13I.
More Information Supplier PageIbrutinib is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. Ibrutinib is applicable as a Btk ligand in the synthesis of a series of PROTACs including P13I.
More Information Supplier PageIbrutinib is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. Ibrutinib is applicable as a Btk ligand in the synthesis of a series of PROTACs including P13I.
More Information Supplier PageIBT6A is an impurity of Ibrutinib, which is a selective, irreversible Bruton tyrosine kinase (Btk) inhibitor with an IC50 of 0.5 nM.
More Information Supplier PageIbudilast (KC-404, AV411, MN166) is a relatively non-selective phosphodiesterase inhibitor with anti-inflammatory and neuroprotective activities.
More Information Supplier PageIbudilast (KC-404, AV411, MN166) is a relatively non-selective phosphodiesterase inhibitor with anti-inflammatory and neuroprotective activities.
More Information Supplier PageIbudilast (KC-404, AV411, MN166) is a relatively non-selective phosphodiesterase inhibitor with anti-inflammatory and neuroprotective activities.
More Information Supplier PageIbuprofen (NSC 256857, Dolgesic) is an anti-inflammatory inhibitor targeting COX-1 and COX-2 with IC50 of 13 μM and 370 μM, respectively.
More Information Supplier PageIbuprofen (NSC 256857, Dolgesic) is an anti-inflammatory inhibitor targeting COX-1 and COX-2 with IC50 of 13 μM and 370 μM, respectively.
More Information Supplier Page
